Illumina reported third‑quarter 2025 revenue of $1.084 billion, up 0.4% year‑over‑year, and GAAP diluted earnings per share of $0.98, down from $4.03 in Q3 2024. Non‑GAAP diluted EPS rose 17% to $1.34, reflecting the company’s adjusted profitability metrics.
Operating profit was $227 million, giving a 21.0% operating margin, slightly below the 22% margin forecast for the full year. Gross margin was 67.6%, down from 68.9% in Q3 2024, due to higher freight, duties, and field‑service costs.
Cash, cash equivalents and short‑term investments at quarter‑end were $1.28 billion, up from $934 million a year earlier. Cash flow from operations was $284 million and free cash flow $253 million after $31 million in capital expenditures. The company repurchased $120 million of shares during the quarter.
Illumina raised its full‑year 2025 guidance to $4.5 billion in revenue, $2.70 in diluted EPS, and a 22% non‑GAAP operating margin. The company also increased its Greater China revenue guidance by $20 million, reflecting a rebound after export restrictions.
Management highlighted continued momentum in the clinical segment, with high‑throughput consumables revenue of $747 million and more than 75% of high‑throughput gigabases shipped on the NovaSeq X platform. The company also launched its Illumina Protein Prep and BioInsight businesses and is pursuing a $350 million acquisition of SomaLogic, expected to close in H1 2026.
The results demonstrate Illumina’s ability to navigate market challenges, maintain strong liquidity, and execute on its multi‑omics strategy while sustaining growth and margin expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.